Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Seung-Yoon | - |
dc.contributor.author | Kim, In-San | - |
dc.date.accessioned | 2021-09-01T22:49:57Z | - |
dc.date.available | 2021-09-01T22:49:57Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 0304-3835 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/68973 | - |
dc.description.abstract | Myeloid lineage immune cells, such as macrophages and dendritic cells, play important roles in the induction of antitumor immunity during the initial stage of the cancer-immunity cycle, eliciting antitumor adaptive immunity by phagocytosing cancer cells and processing cancer-specific antigens, and then presenting these antigens to T cells. During this process, cancer cell phagocytosis can be prevented by inhibitory signals, and the signaling cascades that elicit immune responses against cancer antigens can be inhibited by immunosuppressive myeloid cells in the tumor microenvironment. A number of therapeutic strategies for enhancing cancer cell phagocytosis and promoting antitumor immunity by targeting myeloid lineage cells have recently been developed. Here, we discuss recent advances in cancer immunotherapy that involve the targeting of myeloid lineage immune cells to induce effective antitumor immunity. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER IRELAND LTD | - |
dc.subject | TUMOR-ASSOCIATED MACROPHAGES | - |
dc.subject | RHO-ASSOCIATED KINASE | - |
dc.subject | SUPPRESSOR-CELLS | - |
dc.subject | POOR-PROGNOSIS | - |
dc.subject | SIGNALING PROMOTES | - |
dc.subject | CD47 BLOCKADE | - |
dc.subject | T-CELLS | - |
dc.subject | INHIBITION | - |
dc.subject | RECEPTOR | - |
dc.subject | PHAGOCYTOSIS | - |
dc.title | Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, In-San | - |
dc.identifier.doi | 10.1016/j.canlet.2019.03.018 | - |
dc.identifier.scopusid | 2-s2.0-85063328555 | - |
dc.identifier.wosid | 000466454100005 | - |
dc.identifier.bibliographicCitation | CANCER LETTERS, v.452, pp.51 - 58 | - |
dc.relation.isPartOf | CANCER LETTERS | - |
dc.citation.title | CANCER LETTERS | - |
dc.citation.volume | 452 | - |
dc.citation.startPage | 51 | - |
dc.citation.endPage | 58 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | TUMOR-ASSOCIATED MACROPHAGES | - |
dc.subject.keywordPlus | RHO-ASSOCIATED KINASE | - |
dc.subject.keywordPlus | SUPPRESSOR-CELLS | - |
dc.subject.keywordPlus | POOR-PROGNOSIS | - |
dc.subject.keywordPlus | SIGNALING PROMOTES | - |
dc.subject.keywordPlus | CD47 BLOCKADE | - |
dc.subject.keywordPlus | T-CELLS | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | PHAGOCYTOSIS | - |
dc.subject.keywordAuthor | Macrophages | - |
dc.subject.keywordAuthor | Dendritic cells | - |
dc.subject.keywordAuthor | Phagocytosis | - |
dc.subject.keywordAuthor | Antitumer immunity | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.